BIOMARIN PHARMACEUTICAL INC

BIOMARIN PHARMACEUTICAL INC Share · US09061G1013 · BMRN · 924801 (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of BIOMARIN PHARMACEUTICAL INC
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
28
13
0
0
No Price
01.05.2026 20:00
Current Prices from BIOMARIN PHARMACEUTICAL INC
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
BMRN
USD
01.05.2026 20:00
54,06 USD
0,15 USD
+0,28 %
IEXG: IEX
IEX
BMRN
USD
01.05.2026 19:59
54,07 USD
0,16 USD
+0,30 %
XLON: London
London
0HNC.L
USD
01.05.2026 15:08
54,01 USD
0,10 USD
+0,19 %
XDUS: Düsseldorf
Düsseldorf
BPIRSD13.DUSB
EUR
30.04.2026 17:31
46,50 EUR
0,10 EUR
+0,22 %
XHAN: Hannover
Hannover
BPIRSD13.HANB
EUR
30.04.2026 15:25
46,45 EUR
0,05 EUR
+0,11 %
XHAM: Hamburg
Hamburg
BPIRSD13.HAMB
EUR
30.04.2026 06:07
46,32 EUR
-
XDQU: Quotrix
Quotrix
BPIRSD13.DUSD
EUR
30.04.2026 05:27
46,38 EUR
-
ESG Risk Rating
B- Good
Share Float & Liquidity
Free Float 99,42 %
Shares Float 191,21 M
Shares Outstanding 192,32 M
Invested Funds

The following funds have invested in BIOMARIN PHARMACEUTICAL INC:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
515,07
Percentage (%)
1,21 %
Fund
iShares MSCI USA Islamic UCITS ETF USD (Dist)
Vol. in million
401,68
Percentage (%)
0,24 %
Fund
iShares Edge MSCI USA Minimum Volatility ESG UCITS ETF USD (Acc)
Vol. in million
3.479,23
Percentage (%)
0,20 %
Fund
iShares MSCI World Health Care Sector UCITS ETF USD (Dist)
Vol. in million
717,39
Percentage (%)
0,20 %
Fund
iShares MSCI World Islamic UCITS ETF USD (Dist)
Vol. in million
445,40
Percentage (%)
0,14 %
Company Profile for BIOMARIN PHARMACEUTICAL INC Share
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Company Data

Name BIOMARIN PHARMACEUTICAL INC
Company BioMarin Pharmaceutical Inc.
Symbol BMRN
Website https://www.biomarin.com
Primary Exchange XNAS NASDAQ
WKN 924801
ISIN US09061G1013
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Alexander Hardy
Market Capitalization 12 Mrd.
Country United States of America
Currency USD
Employees 3,4 T
Address 770 Lindaro Street, 94901 San Rafael
IPO Date 2022-11-10
Dividends from 'BIOMARIN PHARMACEUTICAL INC'
Ex-Date Dividend per Share
15.03.2022 0,29 USD

Ticker Symbols

Name Symbol
Düsseldorf BPIRSD13.DUSB
Frankfurt BM8.F
Hamburg BPIRSD13.HAMB
Hannover BPIRSD13.HANB
London 0HNC.L
NASDAQ BMRN
Quotrix BPIRSD13.DUSD
XETRA BM8.DE
More Shares
Investors who hold BIOMARIN PHARMACEUTICAL INC also have the following shares in their portfolio:
AMGEN INC
AMGEN INC Share
AUTODESK INC
AUTODESK INC Share
CIF-C.G.JAPAN EQ.B EUR
CIF-C.G.JAPAN EQ.B EUR Fund
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
DZ BANK CLN E.8633
DZ BANK CLN E.8633 Bond
GILEAD SCIENCES INC
GILEAD SCIENCES INC Share
ILLUMINA INC
ILLUMINA INC Share
INTEL CORP
INTEL CORP Share
JPM-EO.SM.CAP JPMESC DAEO
JPM-EO.SM.CAP JPMESC DAEO Fund
OPTHEA LTD/8)
OPTHEA LTD/8) Depository Receipt
PROCTER GAMBLE CORP
PROCTER GAMBLE CORP Share
QIAGEN NV (alt)
QIAGEN NV (alt) Share
REGENERON PHARMACEUTICALS INC
REGENERON PHARMACEUTICALS INC Share
VERTEX PHARMACEUTICALS INC
VERTEX PHARMACEUTICALS INC Share